[1] Jacobs S, McCully CL, Murphy RF, et al. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates[J]. Cancer Chemother Pharmacol, 2010, 65(5): 817-824.
[2] Dave N, Gudelsky GA, Desai PB. The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis[J]. Cancer Chemother Pharmacol, 2013, 72(2): 349-357.
[3] Miyajima M, Kusuhara H, Takahashi K, et al. Investigation of the effect of active efflux at the bloodbrain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system[J]. J Pharm Sci, 2013, 102(9): 3309-3319.
[4] Blakeley JO, Olson J, Grossman SA, et al. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study[J]. J Neurooncol, 2009, 91(1): 51-58.
[5] Villarroel MC, Pratz KW, Xu L, et al. Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients[J]. Invest New Drugs, 2012, 30(6): 2096-2102.
[6] Martins FC, de Oliveira CF. Chemotherapy and the future: microdialysis as a local administration technique[J]. Eur J Gynaecol Oncol, 2009, 30(1): 5-8.
[7] Martins FC, Santos JL, de Oliveira CF. Microdialysis: improving local chemotherapy in cancer using a mathematical model[J]. Front Biosci (Elite Ed), 2012, 4: 401-409.
[8] Portnow J, Badie B, Chen M, et al. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation[J]. Clin Cancer Res, 2009, 15(22): 7092-7098.
[9] Konings IR, Sleijfer S, Mathijssen RH, et al. Increasing tumoral 5fluorouracil concentrations during a 5day continuous infusion: a microdialysis study[J]. Cancer Chemother Pharmacol, 2011, 67(5): 1055-1062.
[10] Redman LM, Moro C, Dobak J, et al. Association of β2 adrenergic agonist and corticosteroid injection in the treatment of lipomas[J]. Diabetes Obes Metab, 2011, 13(6): 517-522.
[11] Sani SN, Henry K, Bhlke M, et al. The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumorbearing mice: a microdialysis study[J]. Cancer Chemother Pharmacol, 2010, 66(1): 159-169.
[12] Carcaboso AM, Elmeliegy MA, Shen J, et al. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas[J]. Cancer Res, 2010, 70(11): 4499-4508.
[13] 胡凌云, 李亚里. 乳腺癌的早期预警. 国际肿瘤学杂志, 2011, 38(2): 118-120.
[14] Nilsson UW, Abrahamsson A, Dabrosin C. Angiogenin regulation by estradiol in breast tissue: tamoxifen inhibits angiogenin nuclear translocation and antiangiogenin therapy redues breast cancer growth in vivo[J]. Clin Cancer Res, 2010, 16(14): 3659-3669.
[15] Lindahl G, Saarinen N, Abrahamsson A, et al. Tamoxifen, flaxseed, and the lignan enterolactone increase stromaand cancer cellderived IL1Ra and decrease tumor angiogenesis in estrogendependent breast cancer[J]. Cancer Res, 2011, 71(1): 51-60.
[16] Abrahamsson A, Morad V, Saarinen NM, et al. Estradiol, tamoxifen, and flaxseed alter IL1β and IL1Ra levels in normal human breast tissue in vivo[J]. J Clin Endocrinol Metab, 2012, 97(11): E2044-2054.
[17] Aberg UW, Saarinen N, Abrahamsson A, et al. Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo[J]. PLoS One, 2011, 6(9): e25720.
[18] Saarinen NM, Abrahamsson A, Dabrosin C. Estrogeninduced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo[J]. Int J Cancer, 2010, 127(3): 737-745.
[19] Bendrik C, Dabrosin C. Estradiol increases IL8 secretion of normal human breast tissue and breast cancer in vivo[J]. J Immunol, 2009, 182(1): 371-378.
[20] Leifler KS, Svensson S, Abrahamsson A, et al. Inflammation induced by MMP9 enhances tumor regression of experimental breast cancer[J]. J Immunol, 2013, 190(8): 4420-4430.
[21] Hardt M, Lam DK, Dolan JC, et al. Surveying proteolytic processes in human cancer microenvironments by microdialysis and activitybased mass spectrometry[J]. Proteomics Clin Appl, 2011, 5(11-12): 636-643.
[22] Wibom C, Surowiec I, Mrén L, et al. Metabolomic patterns in glioblastoma and changes during radiotherapy: a clinical microdialysis study[J]. J Proteome Res, 2010, 9(6): 2909-2919.
[23] Tabatabaei P, Bergstrom P, Henriksson R, et al. Glucose metabolites, glutamate and glycerol in malignant glioma tumours during radiotherapy[J]. J Neurooncol, 2008, 90(1): 35-39.
[24] Xu BJ, Yan W, Jovanovic B, et al. Microdialysis combined with proteomics for protein identification in breast tumor microenvironment in vivo[J]. Cancer Microenviron, 2010, 4(1): 61-71.
[25] Rogers ML, Brennan PA, Leong CL, et al. Online rapid sampling microdialysis (rsMD) using enzymebased electroanalysis for dynamic detection of ischaemia during free flap reconstructive surgery[J]. Anal Bioanal Chem, 2013, 405(11): 38813888.
[26] Ellebeak Pedersen M, Qvist N, Bisgaard C, et al. Peritoneal microdialysis.early diagnosis of anastomotic leakage after low anterior resection for rectosigmoid cancer[J]. Scand J Surg, 2009, 98(3): 148-154. |